New Treatment Modality: Nivolumab (Opdivo) has been approved for the treatment of patients with previously treated metastatic squamous non-small cell lung cancer (NSCLC)

Last Updated on

June 17, 2015 – Bristol Myers Squipp recently announced that the U.S. Food and Drug Administration (FDA) has approved Nivolumab (Opdivo) injection, for intravenous use, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Nivolumab (Opdivo) is the first PD-1 (programmed death receptor-1) therapy to demonstrate overall survival in previously treated metastatic squamous NSCLC. Nivolumab (Opdivo) demonstrated significantly superior overall survival (OS) vs. docetaxel, with a 41% reduction in the risk of death (hazard ratio: 0.59 [95% CI: 0.44, 0.79; p=0.00025]), in a prespecified interim analysis of a Phase III clinical trial. The median OS was 9.2 months in the Opdivo arm (95% CI: 7.3, 13.3) and 6 months in the docetaxel arm (95% CI: 5.1, 7.3).

Opdivo IIn this context, CheckMate -017 was a landmark Phase III, open-label, randomized, multinational, multicenter clinical trial that evaluated Nivolumab (Opdivo) (3 mg/kg intravenously over 60 minutes every two weeks) (n=135) vs. standard of care, docetaxel (75 mg/m2 intravenously administered every 3 weeks) (n=137), in patients with metastatic squamous NSCLC who had progressed during or after prior platinum doublet-based chemotherapy regimen. This trial included patients regardless of their PD-L1 (programmed death ligand-1) status. The primary endpoint of this trial was overall survival (OS). The trial was stopped based on an assessment conducted by the independent Data Monitoring Committee (DMC), which concluded that the study met its endpoint, demonstrating superior OS in patients receiving  Nivolumab (Opdivo) compared to docetaxel. The prespecified interim analysis was conducted when 199 events (86% of the planned number of events for final analysis) were observed (86 in the Opdivo arm and 113 in the docetaxel arm).

Currently, Nivolumab (Opdivo) is the only FDA-approved monotherapy to demonstrate proven superior OS compared to standard of care in more than 15 years in previously treated metastatic squamous NSCLC. “The FDA approval of Nivolumab (Opdivo)introduces an entirely new treatment modality that has demonstrated unprecedented results for the treatment of previously treated metastatic squamous NSCLC, with the potential to replace chemotherapy for these patients,” said Dr. Suresh Ramalingam, MD, Professor and Director of Medical Oncology, Winship Cancer Institute of Emory University. “This milestone brings to fruition the long-held hope that immuno-oncology medicines can be significantly effective in this difficult-to-treat population.”

Therapy of eligible patients with Nivolumab (Opdivo) comes with a price, however. The clinical safety profile of Nivolumab (Opdivo) in squamous NSCLC was established in CheckMate -063, a Phase II single-arm, open-label, multinational, multicenter trial of Nivolumab (Opdivo), administered as a single agent in patients with metastatic squamous NSCLC who have progressed after receiving a platinum-based therapy and at least one additional systemic treatment regimen (n=117). Patients received 3 mg/kg of Nivolumab (Opdivo) administered intravenously over 60 minutes every 2 weeks. This trial included patients regardless of their PD-L1 status. The most common adverse reactions (reported in ≥20% of patients) were fatigue (50%), dyspnea (38%), musculoskeletal pain (36%), decreased appetite (35%), cough (32%), nausea (29%), and constipation (24%). Serious adverse reactions occurred in 59% of patients receiving Nivolumab (Opdivo). The most frequent serious adverse reactions reported in ≥2% of patients were dyspnea, pneumonia, chronic obstructive pulmonary disease exacerbation, pneumonitis, hypercalcemia, pleural effusion, hemoptysis, and pain. Nivolumab (Opdivo)was discontinued due to adverse reactions in 27% of patients. Twenty-nine percent of patients receiving Nivolumab (Opdivo) had a drug delay for an adverse reaction.

With at least 10 months of minimum follow up for all patients, the confirmed objective response rate (ORR), the study’s primary endpoint, was 15% (17/117) (95% CI = 9, 22) of which all were partial responses. The median time to onset of response was 3.3 months (range: 1.7 to 8.8 months) after the start of Nivolumab (Opdivo)treatment. Seventy-six percent of Nivolumab (Opdivo) responders (13/17 patients) had ongoing responses with durability of response ranging from 1.9+ to 11.5+ months; 10 of these 17 (59%) patients had durable responses of 6 months or longer.

“The approval of Nivolumab (Opdivo) for the treatment of previously treated metastatic squamous non-small cell lung cancer is a major advancement in delivering extended survival for patients fighting this deadly disease,” said Andrea Ferris, President and Chairman, Lungevity Foundation. “We are very excited for an immuno-oncology therapy to enter the market and offer options and hope for many of our patients.

Previously, Nivolumab (Opdivo) was approved by the FDA for the tratment of advanced melanoma.

Tags: , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login

Notify of
Sling TV Save Money Coupon 2018

Hi I am so excited I found your blog page, I really found you by mistake, while I
was browsing on Digg for something else, Anyways I am here now and would just like to say many thanks for a incredible post and a all
round enjoyable blog (I also love the theme/design), I don’t have time to look over it all at the moment but I have saved
it and also added your RSS feeds, so when I have time I
will be back to read more, Please do keep up
the fantastic work.

descargar facebook

Very nice post. I simply stumbled upon your blog and wanted to mention that I’ve really enjoyed
browsing your blog posts. After all I’ll
be subscribing in your feed and I am hoping you write once more
very soon!

descargar facebook

I’m extremely inspired along with your writing skills as neatly as
with the format to your blog. Is that this a paid subject or did you
customize it yourself? Either way stay up the nice quality writing, it is rare
to peer a great blog like this one these days..

descargar facebook

This is my first time pay a quick visit at here and i
am in fact pleassant to read all at single place.

descargar facebook

I just couldn’t depart your web site before suggesting that I really loved
the standard info an individual provide to your guests? Is gonna be
back incessantly to inspect new posts

descargar facebook

There’s certainly a lot to know about this
issue. I like all of the points you have made.

descargar facebook

I was suggested this website by my cousin. I’m not sure whether
this post is written by him as nobody else know such detailed about my
problem. You are wonderful! Thanks!

descargar facebook

I’d like to thank you for the efforts you have put in penning this
site. I am hoping to view the same high-grade content by you later on as
well. In fact, your creative writing abilities has inspired me to
get my own website now 😉

descargar facebook

Hello, I enjoy reading all of your article post.
I like to write a little comment to support you.

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Ancestry launches DNA health service that will compete with 23andMe October 15, 2019
    Ancestry has long appealed to people eager to learn about their family roots. Now the company known for its popular DNA kits is diving into a new area of discovery—health.
  • Improving research with more effective antibodies October 15, 2019
    A new study points to the need for better antibody validation, and outlines a process that other labs can use to make sure the antibodies they work with function properly.
  • New DNA 'clock' could help measure development in young children October 15, 2019
    Scientists have developed a molecular "clock" that could reshape how pediatricians measure and monitor childhood growth and potentially allow for an earlier diagnosis of life-altering development disorders.
  • DNA fracturing rewires gene control in cancer October 15, 2019
    Understanding the mechanisms that mediate widespread DNA damage in the cancer genome is of great interest to cancer physicians and scientists because it may lead to improved treatments and diagnosis. In this study, a multi-institutional team led by researchers at Baylor College of Medicine has brought attention to genomic structural variation as a previously unappreciated […]
  • Most genetic studies use only white participants – this will lead to greater health inequality October 15, 2019
    Few areas of science have seen such a dramatic development in the last decade as genomics. It is now possible to read the genomes of millions of people in so-called genome-wide association studies. These studies have identified thousands of small differences in our genome that are linked to diseases, such as cancer, heart disease and […]